Insusense

Insusense Therapeutics is a Swedish biotechnology company focused on developing novel disease-modifying therapies for neurodegenerative disorders, with a primary emphasis on Alzheimer's disease. The company leverages expertise in protein aggregation to develop monoclonal antibodies that specifically target the most neurotoxic forms of amyloid-beta. Founded by pioneers in the field, including Lars Lannfelt, Insusense aims to provide highly selective treatments that minimize side effects while maximizing efficacy. Their lead programs are currently in the pre-clinical stage, building on the scientific legacy of successful Alzheimer's research in the Uppsala region.